Skip to main content
Premium Trial:

Request an Annual Quote

This Week in NEJM: Jun 30, 2011

Premium

Published online in advance in NEJM this week, The National Lung Screening Trial Research Team presents findings from a study of the associations between reduced lung cancer mortality and low-dose computed tomographic screening. So far, the use of screening has been ineffective against the mortality rate in lung cancer, the authors write. But studies on low-dose helical computed tomography show that the technology can detect many early-stage lung tumors. In this study, the researchers randomly assigned 53,454 people at high risk for lung cancer into two groups, one of which received three annual screenings with low-dose CT, and the other of which received three screenings with single-view posteroanterior chest radiography. The team found that low-dose CT had a positive screening test rate of 24.2 percent, compared with 6.9 percent for radiography. There were 247 deaths from lung cancer per 100,000 people in the CT group, and 309 deaths per 100,000 people in the radiography group, the authors write, representing a relative reduction in mortality from lung cancer of 20 percent with low-dose CT screening. "Screening with the use of low-dose CT reduces mortality from lung cancer," they add.

And in an editorial in NEJM this week, the Robert Wood Johnson Foundation's Harold Sox says its time for policy makers to pay attention to new studies on screening for lung cancer. Recent studies have shown that low-dose CT screening is helping to catch lung cancer earlier and has an effect on lung cancer mortality, Sox says. So how should policy makers, who are responsible for drafting screening guidelines and deciding insurance coverage, respond? "Policymakers should wait for cost-effectiveness analyses of the NLST data, further follow-up data to determine the amount of overdiagnosis in the NLST, and, perhaps, identification of biologic markers of cancers that do not progress," Sox says. "Modeling should provide estimates of the effect of longer periods of annual screening and the effect of better adherence to screening and diagnostic evaluation. Systematic reviews that include other, smaller lung-cancer screening trials will provide an overview of the entire body of evidence. Finally, it may be possible to define subgroups of smokers who are at higher or lower risk for lung cancer and tailor the screening strategy accordingly." Patients at risk for lung cancer and their physicians should inform themselves of the advantages and disadvantages of new screening methods, he adds.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.